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Role for serial prenatal anti-Vel quantitative 
serologic monitoring with 2-ME serum 
treatment during pregnancy: case report
    W.J. Linz, J.T. Fueger, S. Allen, and S.T. Johnson
Anti-Vel is an uncommon antibody to a high-prevalence antigen. 
Its clinical significance and management in the prenatal setting are 
not well characterized. We present a case that demonstrates the 
utility of serial prenatal anti-Vel quantitative serologic monitoring 
with 2-ME serum treatment during pregnancy. The patient is a 
23-year-old Hispanic woman with history of prior pregnancy and 
prior transfusion who was discovered to have an antibody to the 
high-prevalence Vel antigen in the first trimester (week 7) of her 
second pregnancy. Interval measurements of the serologic antibody 
titers were performed during the next 26 weeks. The untreated se-
rum (IgM and IgG) titer increased from a baseline of 4 to 16 during 
that interval, while the 2-ME (presumed IgG component) titer re-
mained stable at 4. Responding to ultrasound findings suspicious 
for fetal anemia, the child was delivered without complications at 
34 weeks’ gestation. At birth, the DAT was negative and there was 
no evidence of HDN.  Placed in the context of other similar reports, 
this case demonstrates the importance of separately reporting the 
IgG fraction (after either DTT treatment or 2-ME treatment) from 
the untreated (IgM and IgG) fraction and the importance of cor-
relating the treated serum titer with potential clinical significance. 
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Vel is a high-prevalence antigen first described by Sussman et al. in 1952 in association with a trans-fusion reaction.1 Although several additional cases 
quickly confirmed these authors’ findings,2 our knowledge 
of the Vel antigen (collection) remains incomplete. The 
presence of the Vel-negative phenotype in the general pop-
ulation is estimated to be 1 in 4000 individuals.3 Vel alloim-
munization can be mediated through IgG or IgM. Anti-Vel 
is thought to be associated rarely with hemolytic disease of 
the fetus and newborn (HDFN) because many examples of 
anti-Vel are mostly IgM and Vel is weakly expressed on the 
surface of fetal RBCs. Although the risk may be low, it is rea-
sonable to monitor prenatal serologic titers serially during 
pregnancy.4 The findings published in a recent case report 
by van Gammeren et al.,5 of severe HDFN from anti-Vel, 
support this approach. The van Gammeren case report de-
scribes discovery in a prenatal patient of an anti-Vel, which 
at initial presentation was determined to be composed ex-
clusively of IgM. At the end of the pregnancy, an anti-Vel 
titer of 64 was demonstrated in untreated serum, whereas 
the DTT-treated serum (presumed IgG content) titer rose 
to 16. In their case, the infant exhibited severe jaundice and 
reticulocytosis. As a corollary to the van Gammeren case re-
port, we present a case of an anti-Vel for which the IgG titer 
as determined by 2-ME treatment was stable through preg-
nancy despite a significant rise in the titer of the anti-Vel in 
the untreated serum. At birth, the child showed no evidence 
of HDFN. This case report supports the importance of serial 
determination of the prenatal IgG titer to help assess risk 
of HDFN.
Case Report
 A 23-year-old Hispanic woman, with a history of prior 
blood transfusion and one successful pregnancy, presented 
initially early in the first trimester of the index pregnancy. 
Her RBCs were typed as group O, D+. Routine serologic 
testing demonstrated variable reactivity using gel technolo-
gy. The autocontrol was negative. Further testing using tube 
technology with PEG as enhancement also demonstrated 
variable weak reactivity, again with no specificity. No reac-
tivity was demonstrated when using tube technology with 
LISS. A repeat serologic evaluation was performed 4 weeks 
later to help clarify the nature of this reactivity. The subse-
quent serologic evaluation demonstrated reactivity with all 
RBCs tested whether using gel or test tube technology with 
LISS or PEG methods. The autocontrol was consistently 
negative. As an antibody to a high-prevalence antigen was 
suspected, the sample was referred to a large nationally rec-
ognized immunohematology reference laboratory. With use 
of rare RBCs lacking various high-prevalence antigens, re-
activity was determined to be that of anti-Vel. The patient’s 
RBCs were shown to lack the Vel antigen. The initial quan-
titative serologic titer was 4 when tested against Vel+ RBCs 
using both 2-ME-treated and untreated serum. The Marsh 
score ranged from 14 with untreated serum to 4 with 2-ME-
treated serum. The developing baby’s RBCs were presumed 
to be Vel+ as the father’s RBCs were demonstrated to ex-
press the Vel antigen. Subsequent quantitative serologic 
monitoring was performed in approximately 4- to 6-week 
intervals for the next 20 weeks of pregnancy (Table 1).
 At 33 2/7 weeks’ gestation, Doppler ultrasonography 
showed an increase in middle cerebral artery velocity (>1.5 
multiples of the median [MoM] for gestational age) suspi-
cious for fetal anemia. This finding was a significant change 
from previous Doppler ultrasound studies and correspond-
ed with the change in quantitative serologic titer of the 
Case Report
IMMUNOHEMATOLOGY, Volume 26, Number 1, 2010 9
untreated serum from 4 at presentation to 16 by week 26 
(Table 1). A multidisciplinary risk-benefit analysis, includ-
ing consideration of potential maternal and fetal need for 
transfusion with an extremely limited blood supply (two 
available units), the unpredictable timing issues encoun-
tered with induction, and the limited time-availability for 
transfusion after thawing the available units, prompted 
the decision to move toward delivery in a manner that op-
timized the availability of blood for the newborn, if it was 
indeed anemic. The patient underwent cesarean delivery at 
34 3/7 weeks’ gestational age, 2 days after the initial admin-
istration of Celestone to promote fetal pulmonary maturity. 
A 3088-g male newborn with Apgar scores of 7 at 1 min-
ute and 9 at 5 minutes was born without complication. The 
child’s RBCs typed as group A, D+, and the antibody screen 
was negative. Initial laboratory data were also remarkable 
for a Hb level of 16.6 g/dL (normal range), reticulocyte count 
of 3.5% (normal range), and negative DAT. Approximately 
1 week after delivery, a mild rise in bilirubin was observed, 
reaching a peak of 10 mg/dL. Given that the DAT and the 
initial screen were negative, the mild hyperbilirubinemia 
was thought not likely to have resulted from transplacen-
tal anti-Vel or a possible anti-A from a group O mother. 
Moreover, although laboratory data are a bit limited, there 
was no evidence of anemia or hemolysis. Importantly, the 
mild hyperbilirubinemia quickly resolved, and the newborn 
was released to home and is doing well approximately 10 
months after birth.
performed at the immunohematology reference laboratory 
used tube method. The patient’s serum was diluted in 6% 
albumin. A 30-minute 37°C incubation was performed, fol-
lowed by a saline IAT (Anti-IgG, ImmucorGamma Inc.).6 
Reaction scoring was performed using the system originally 
described by Marsh.7 The patient’s serum was treated with 
2-ME (Fisher Scientific Co., Hanover Park, IL) and dialyzed 
overnight using dialysis membranes (Spectra/Por2, 12,000 
to 14,000 dalton molecular weight cut-off [MWCO], Spec-
trum Laboratories, Inc., Rancho Domingtuez, CA) in PBS, 
pH 7.3. Dialyzed serum was tested using the methods previ-
ously described.
Discussion
 This case adds to the limited published information 
regarding the natural history of anti-Vel in the prenatal 
setting, and it supports the value of sorting immunoglobu-
lin classes as an aid to proper prenatal management. It is 
worth noting that at initial presentation, weak, variable se-
rologic reactivity was demonstrated. Despite use of several 
standard methods, specificity could not be assigned to the 
serologic reactivity. In the initial serologic evaluation, reac-
tivity was present using gel technology and tube technology 
with PEG as enhancement. Tube testing with LISS showed 
no reactivity. Although a LISS tube method is considered 
an appropriate antibody detection method in the prenatal 
setting,8 this method would not have detected the antibody. 
A repeat study approximately 7 weeks after the initial study 
did demonstrate the presence of strong serologic reactivity 
using tube testing with LISS and PEG as well as with gel. 
The titer of the untreated serum and 2-ME–treated serum 
was 4. Presumably, late in the first trimester of pregnancy 
the mother was exposed to fetal RBCs expressing the Vel 
antigen because by week 14 she demonstrated a specific se-
rologic immune response. Interestingly, for the remainder 
of the pregnancy, the titer of the anti-Vel in the 2-ME (pre-
sumed IgG component)–treated serum remained stable al-
though the titer in the untreated serum (presumed IgM and 
IgG) increased by two dilutions. This observation may be 
useful to laboratories without the capacity to treat patient 
serum with 2-ME or DTT. Namely, in this case anti-Vel titer 
in the untreated serum appeared to rise before the anti-Vel 
IgG titer in the 2-ME–treated serum.
 The rise in antibody titer in the untreated serum com-
bined with the abnormal Doppler velocimetry prompted 
the preterm delivery. At birth, the DAT and antibody screen 
were negative, and the hemoglobin and reticulocyte count 
were in the normal range. As the anti-Vel present in the ma-
ternal serum contained an IgG component, the negative DAT 
suggests that Vel antigen on the fetal RBCs may either be 
weakly or partially expressed9 or the antibody avidity to the 
antigen was poor. Regardless, in this case, an anti-Vel titer of 
4 does not appear to be independently sufficient for HDFN, 
whereas a titer of 16 in the case reported by van Gammeren 
et al.5 was associated with HDFN. The cause of the rise in 
Methods
 ABO and D testing and DAT were performed using 
commercially available reagents according to manufactur-
ers’ protocols using tube method (Immucor Gamma Inc., 
Norcross, GA). Antibody detection and identification were 
performed using either gel technology according to the man-
ufacturer’s protocol using reagent cells (RBCs 0.8% Surgis-
creen and reagent RBCs 0.8% Resolve Antigram, ID-MTS 
Gel Test; Ortho-Clinical Diagnostics, Raritan, NJ) or tube 
method with commercially available cells and reagents 
(PEG and LISS, Immucor Gamma Inc.). Titration studies 

























N/A N/A N/A N/A
14 Anti-Vel 4 24 4 24
18 Anti-Vel 4 27 4 14
22 Anti-Vel 8 N/T N/T N/T
26 Anti-Vel 16 25 4 18
34 Anti-Vel 16 30 4 14
N/A = not applicable; N/T = not tested.
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the bilirubin level after birth remains uncertain, although 
liver immaturity is the most likely explanation. Finally, the 
abnormal Doppler velocimetry in the absence of true fetal 
anemia reflects the inherent limitations of a screening test 
that is known to have a 12 percent rate of false-positive re-
sults.10
 The Vel antigen (collection) and anti-Vel remain enig-
matic and are in need of further study. To date, it is known 
that the Vel-negative phenotype is universally uncommon. 
The incidence of the Vel-negative phenotype in the Hispanic 
population is not known with certainty. Anti-Vel is famous-
ly associated with in vitro hemolysis, severe transfusion re-
actions, and shortened RBC survival,11 although there is at 
least one case report of Vel+ blood being successfully trans-
fused to a recipient possessing anti-Vel.12 An auto-anti-Vel13 
has been described, although it is uncertain to what degree 
the autoantibody contributed to the patient’s RBC destruc-
tion. Anti-Vel can be difficult to detect, and it can simulate 
the serologic profile of a cold-reactive autoantibody, with 
disastrous consequences if improper analytic methods are 
used.14 The Vel antigen appears to have a variable antigenic 
expression and appears to be best expressed on adult cells.
  When viewed in concert with the recent case report by 
van Gammeren et al.,5 our case report further supports the 
need not only to properly identify anti-Vel in the prenatal 
setting but also to perform serial quantitative serologic 
monitoring using methods to clearly separate the IgG frac-
tion (DTT treatment or 2-ME treatment) from the untreat-
ed (IgM and IgG) fraction. Although both the untreated 
and treated serum titer and score results may be reported, 
changes in the treated serum fraction, representing the IgG 
component, may be a better trigger to initiate additional 
clinical investigation. Additional cases may help identify 
the most appropriate critical 2-ME or DTT titer for anti-
Vel.
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